Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Key Takeaways

• FDA grants priority review for ifinatamab deruxtecan in ES‑SCLC.
• BLA based on Phase 2 IDeate‑Lung01 trial with 187 patients.
• First‑in‑class B7‑H3 ADC could fill unmet SCLC treatment gap.
• Daiichi Sankyo and Merck partnership expands global ADC portfolio.
• PDUFA decision scheduled for Oct 10 2026 under RTOR, Orbis.

Pulse Analysis

Small cell lung cancer remains one of the deadliest thoracic malignancies, accounting for roughly 12% of U.S. lung‑cancer diagnoses and offering limited therapeutic options after platinum‑based regimens fail. The overexpression of B7‑H3 on tumor cells provides a compelling target, yet no B7‑H3‑directed therapies have reached market approval. Ifinatamab deruxtecan leverages Daiichi Sankyo’s DXd ADC platform to deliver a potent topoisomerase I inhibitor directly to B7‑H3‑positive cells, aiming to boost response rates while sparing normal tissue.

The FDA’s Priority Review designation reflects the strength of the IDeate‑Lung01 Phase 2 trial, which enrolled 187 patients across three continents and demonstrated a robust objective response rate at both 8 mg/kg and 12 mg/kg dosing. Coupled with Breakthrough Therapy status, the application benefits from Real‑Time Oncology Review and Project Orbis, accelerating the evaluation timeline and enabling coordinated international assessment. The PDUFA target of October 10, 2026 gives investors and clinicians a clear horizon for potential market entry.

Strategically, the collaboration underscores Merck’s commitment to expanding its oncology ADC portfolio beyond PD‑1/PD‑L1 inhibitors, while Daiichi Sankyo capitalizes on its proprietary DXd technology to diversify revenue streams. Success could catalyze further development of B7‑H3‑targeted agents across other solid tumors, reinforcing the competitive landscape of next‑generation ADCs. Stakeholders will watch the upcoming decision closely, as it may set a precedent for accelerated pathways in high‑unmet‑need cancers.